AMGN vs GILD
By Alex · Tickerpine
Amgen Inc. vs Gilead Sciences, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | AMGN | GILD |
|---|---|---|
| Price | $358.33 | $127.88 |
| Market cap | $193.39B | $158.77B |
| P/E ratio | 24.9 | 17.4 |
| ROE | 101.32% | 43.36% |
| Profit margin | 20.96% | 30.99% |
| Revenue growth | 5.80% | 4.40% |
| Dividend yield | 2.81% | 2.56% |
| Beta | 0.42 | 0.33 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
AMGN vs GILD in plain English
- AMGN is the bigger company — about 1.2× the market cap of GILD.
- GILD is cheaper on earnings (P/E 17.4 vs 24.9).
- AMGN earns a higher return on equity (101% vs 43%).
- AMGN is growing revenue faster (6% vs 4%).
- AMGN has the higher dividend yield (2.81% vs 2.56%).
How would $1,000 have done in each?
AMGN return calculator
See what $1,000 in Amgen Inc. would be worth today.
GILD return calculator
See what $1,000 in Gilead Sciences, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.